This trial is evaluating whether ADAPT+ will improve 4 primary outcomes and 10 secondary outcomes in patients with Obesity. Measurement will happen over the course of 8 weeks after baseline.
This trial requires 108 total participants across 2 different treatment groups
This trial involves 2 different treatments. ADAPT+ is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Obesity, defined as an excess of body weight relative to body surface area, can be present for a number of reasons, including insulin resistance and genetic susceptibility. However, many individuals who are of normal weight are also insulin resistant, which suggests that there are additional signs of obesity, in addition to the presence of excess fat. The presence of any of these signs, including excess subcutaneous fat, may constitute a clinical diagnosis of obesity. Further investigation, in the form of a large scale randomized trial, would be required to confirm the absence of obesity as a diagnosis. Results from a recent paper, obesity appeared to be associated with an increased incidence of certain cardiovascular diseases, but no conclusive evidence of any other signs of (or diseases of) obesity.
Results from a recent clinical trial obtained in our study support the existence of a multifactorial etiology of obesity. Effective and targeted lifestyle modification and treatment for obesity can reduce the negative consequences of obesity in health-related fields.
A variety of influences including biological (e.g. genetic and environmental) predisposition, and behavior (e.g. energy intake and physical activity). Obesity is also influenced by social (e.g. economic environment and peer influence) and environmental factors.
Obesity is a major risk factor for several chronic diseases, including Type 2 diabetes and coronary artery disease. It is estimated that by 2030, 37% of the US population will be obese. Obesity is also considered a modifiable risk indicator for several cancers.
Most patients with obesity are diagnosed at weight-loss clinics but continue to lose the weight following the diagnosis and often revert. As the prevalence of obesity continues to increase, there are growing demands on the obesity treatment market that may prompt new practices for the treatment of chronic conditions associated with obesity.
Recent findings suggests there are multiple reasons that contribute to obesity and that each reason should be addressed. It also demonstrates the need to address the factors of social pressure, diet, and work stress that can precipitate or worsen the problem of obesity.
Currently, there isn’t any new treatment for obesity yet. However, there are some new discoveries of why overweight people are still obese, because obesity is usually due to both genetic factors and environmental factors. There are four main reasons: the metabolism of fat in the body is not as efficient as it needs to be; there's not enough energy to burn fat; there's not sufficient insulin to regulate fat uptake (the fat cells do not respond as well to insulin, which makes energy not available); and the brain and adipose tissue do not regulate weight appropriately.
This observational study provides preliminary evidence for both long-term weight loss and reduction in cardiovascular risk factors in a subgroup of people receiving adjuvant treatments during early-onset type 2 diabetes. As well as a reduction in the proportion of people remaining overweight and obese at 7 or 12-months follow-up, this study also has important clinical and public health implications. These results, obtained using a clinical trial design relying on treatment assignment rather than a naturalistic study, are strongly suggestive of this practice, given that it is not yet established clinically how long the long term effects of treatment to persist.
Findings of this study suggest a positive relationship between adaptive behavior and HRQOL improvement. Future research with larger samples is needed to confirm these results.
Clinicians have the opportunity for research that leads to improved treatments, which in the long run can potentially improve the care of their patients, especially those who are obese and have a great interest in the disease, because they have so much to lose or gain.